GENETICS IN ENDOCRINOLOGY: Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts
- PMID: 26646938
- DOI: 10.1530/EJE-15-1028
GENETICS IN ENDOCRINOLOGY: Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts
Abstract
The calcium-sensing receptor (CASR) is the main calcium sensor in the maintenance of calcium metabolism. Mutations of the CASR, the G protein alpha 11 (GNA11) and the adaptor-related protein complex 2 sigma 1 subunit (AP2S1) genes can shift the set point for calcium sensing causing hyper- or hypo-calcemic disorders. Therapeutic concepts for these rare diseases range from general therapies of hyper- and hypo-calcemic conditions to more pathophysiology oriented approaches such as parathyroid hormone (PTH) substitution and allosteric CASR modulators. Cinacalcet is a calcimimetic that enhances receptor function and has gained approval for the treatment of hyperparathyroidism. Calcilytics in turn attenuate CASR activity and are currently under investigation for the treatment of various diseases. We conducted a literature search for reports about treatment of patients harboring inactivating or activating CASR, GNA11 or AP2S1 mutants and about in vitro effects of allosteric CASR modulators on mutated CASR. The therapeutic concepts for patients with familial hypocalciuric hypercalcemia (FHH), neonatal hyperparathyroidism (NHPT), neonatal severe hyperparathyroidism (NSHPT) and autosomal dominant hypocalcemia (ADH) are reviewed. FHH is usually benign, but symptomatic patients benefit from cinacalcet. In NSHPT patients pamidronate effectively lowers serum calcium, but most patients require parathyroidectomy. In some patients cinacalcet can obviate the need for surgery, particularly in heterozygous NHPT. Symptomatic ADH patients respond to vitamin D and calcium supplementation but this may increase calciuria and renal complications. PTH treatment can reduce relative hypercalciuria. None of the currently available therapies for ADH, however, prevent tissue calcifications and complications, which may become possible with calcilytics that correct the underlying pathophysiologic defect.
© 2016 European Society of Endocrinology.
Similar articles
-
Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected familial hypocalciuric hypercalcemia.Endocrine. 2017 Mar;55(3):741-747. doi: 10.1007/s12020-017-1241-5. Epub 2017 Feb 7. Endocrine. 2017. PMID: 28176280
-
Calcium-sensing-related gene mutations in hypercalcaemic hypocalciuric patients as differential diagnosis from primary hyperparathyroidism: detection of two novel inactivating mutations in an Italian population.Nephrol Dial Transplant. 2014 Oct;29(10):1902-9. doi: 10.1093/ndt/gfu065. Epub 2014 Aug 7. Nephrol Dial Transplant. 2014. PMID: 25104082
-
Familial Hypocalciuric Hypercalcemia Types 1 and 3 and Primary Hyperparathyroidism: Similarities and Differences.J Clin Endocrinol Metab. 2016 May;101(5):2185-95. doi: 10.1210/jc.2015-3442. Epub 2016 Mar 10. J Clin Endocrinol Metab. 2016. PMID: 26963950
-
Diseases associated with calcium-sensing receptor.Orphanet J Rare Dis. 2017 Jan 25;12(1):19. doi: 10.1186/s13023-017-0570-z. Orphanet J Rare Dis. 2017. PMID: 28122587 Free PMC article. Review.
-
Calcimimetic Use in Familial Hypocalciuric Hypercalcemia-A Perspective in Endocrinology.J Clin Endocrinol Metab. 2017 Nov 1;102(11):3933-3936. doi: 10.1210/jc.2017-01606. J Clin Endocrinol Metab. 2017. PMID: 28945857 Free PMC article. Review.
Cited by
-
Cinacalcet Reverses Short QT Interval in Familial Hypocalciuric Hypercalcemia Type 1.J Clin Endocrinol Metab. 2024 Jan 18;109(2):549-556. doi: 10.1210/clinem/dgad494. J Clin Endocrinol Metab. 2024. PMID: 37602721 Free PMC article.
-
Familial hypocalciuric hypercalcemia and related disorders.Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):609-619. doi: 10.1016/j.beem.2018.05.004. Epub 2018 May 26. Best Pract Res Clin Endocrinol Metab. 2018. PMID: 30449544 Free PMC article. Review.
-
Case Report: Calcium sensing receptor gene gain of function mutations: a case series and report of 2 novel mutations.Front Endocrinol (Lausanne). 2023 Aug 15;14:1215036. doi: 10.3389/fendo.2023.1215036. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37654565 Free PMC article.
-
Neonatal Severe Hyperparathyroidism: Novel Insights From Calcium, PTH, and the CASR Gene.J Clin Endocrinol Metab. 2020 Apr 1;105(4):1061-78. doi: 10.1210/clinem/dgz233. J Clin Endocrinol Metab. 2020. PMID: 31778168 Free PMC article.
-
Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations.J Endocrinol Invest. 2025 Apr;48(4):831-844. doi: 10.1007/s40618-024-02496-y. Epub 2024 Nov 28. J Endocrinol Invest. 2025. PMID: 39607645 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources